EMEA-002542-PIP01-18

Key facts

Active substance
sutimlimab
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0211/2019
PIP number
EMEA-002542-PIP01-18
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Treatment of primary Cold Agglutinin Disease
Route(s) of administration
Intravenous use
Contact for public enquiries
Bioverativ USA, Inc.

Tel.: +31 356991400
E-mail: eumedinfo.gz@sanofi.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating